 Earlier this month, biotech giant Amgen Inc NASDAQ: AMGN announced a 1.9 billion buyout of Five Prime Therapeutics Inc NASDAQ: FPRX that outlasted around 15 potential collaborators. Background: Amgens interest in FPRX goes back to 2019 when it, alongside others not named in the SEC filing, tried to bet on FPRXs pipeline. 